Investing

Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price

Johnson and Johnson has quietly become one of the best-performing mega-caps of the past year, but with a fresh pullback and a pipeline firing on multiple cylinders, the bigger question is whether the next leg higher finally breaks through to…

By Vandita Jadeja
Published July 15, 2026, 1:29pm ET · 3 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

A close-up, low-angle shot of a white rectangular corporate sign for Johnson & Johnson. The company's name is written in a distinctive red script, with 'MEDICAL DEVICES COMPANIES' in a smaller, gray sans-serif font below. Sunlight creates a bright lens flare on the left side of the sign, with blurred green tree foliage and a clear blue sky in the background. A white light pole is visible on the right, and parts of a modern building with blue-tinted windows can be seen in the distance.
The distinctive Johnson & Johnson sign stands as a symbol of the company's long-standing presence and consistent financial performance, underpinning its impressive dividend growth record. © Mario Tama / Getty Images News via Getty Images

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is up 24.03% year to date and 65.92% over the past year, riding oncology strength and a raised full-year outlook. Our proprietary model sees room to run.

Our 24/7 Wall St. price target for JNJ is $277.85, implying 9.45% upside from the current $253.85. The recommendation is buy with 90% confidence, high by our standards for a mega-cap.

An infographic titled 'JNJ · NYSE · Johnson & Johnson 12-Month Price Prediction' with a green 24/7 WALL ST. logo at the top right. The 'THE CALL' section displays the Current Price of $253.85 (as of July 15, 2026) with an arrow pointing to the Price Target of $277.85, indicating a 'BUY' rating and '+9.45% UPSIDE' with High Confidence (90%). The 'HOW WE GOT THERE' section shows a bar chart representing Trailing P/E Price: $253.85, Forward P/E Price: $249.15, and Analyst Target ($259): Weighted, leading to a Weighted Base: $253.05. The 'OUR ADJUSTMENTS' section is a flowchart with steps: '247Factor: +1.098x' (green plus), 'Sector Momentum & Consensus' (green plus), 'Low Volatility & Position' (green plus), 'Earnings Weakness' (red minus), culminating in the 'FINAL TARGET: $277.85'. The 'BULL CASE What Could Go Right' section lists three points with upward trend icons: Oncology Momentum (DARZALEX, CARVYKTI, TREMFYA), Pipeline & Approvals (ICOTYDE, VARIPULSE Pro, TECVAYLI+), and Planned Orthopaedics Separation & Double-Digit Growth Goal, with a Bull Case Target: $290.54. The 'BEAR CASE What Could Go Wrong' section lists three points with downward trend icons: STELARA Biosimilar Erosion (-59.7% YoY), Litigation Charges & Net Income Decline (-52.4%), and Patent Expiring & FX Headwinds, with a Bear Case Target: $236.59. The 'THE BOTTOM LINE' section reiterates 'BUY $277.85 +9.45% Upside' and provides a summary text. The 24/7 WALL ST. logo is also at the bottom right of the infographic.
24/7 Wall St.

24/7 Wall St. Price Target Summary

Metric Value
Current Price $253.85
24/7 Wall St. Price Target $277.85
Upside 9.45%
Recommendation BUY
Confidence Level 90%

A Year of Accelerated Growth Is Playing Out

JNJ delivered Q1 2026 revenue of $24.06 billion, up 9.9% year over year, with adjusted EPS of $2.70 beating the $2.6773 consensus. Q2 2026 reinforced the trajectory with reported sales of $25.3 billion (up 6.6%) and adjusted EPS of $2.90, prompting another guidance raise.

Management now targets full-year revenue of $100.30 billion to $101.30 billion and adjusted EPS of $11.45 to $11.65. The stock traded as low as $155.89 in the past 52 weeks and now sits just below its $269.43 high after a 5.01% pullback in the last week.

JNJ price target

Why Bulls See a Breakout Above $290

Oncology remains the engine. DARZALEX grew 22.5% to $3.96 billion in Q1, TREMFYA surged 68.3%, CARVYKTI jumped 62.1%, and RYBREVANT/LAZCLUZE climbed 82.7%. Recent approvals for ICOTYDE, VARIPULSE Pro, and TECVAYLI plus DARZALEX FASPRO extend the runway.

Management committed to double-digit growth by decade’s end, and the planned Orthopaedics separation could unlock a valuation re-rating. Our bull case price target over the next 12 months is $290.54, a 14.45% total return.

What Could Go Wrong

STELARA collapsed 59.7% to $656 million as biosimilar competition intensified, and litigation charges of $330 million weighed on GAAP net income, which fell 52.4%.

Bulls view the decline as optics driven by TREMFYA absorbing STELARA share, with the litigation charge running as a non-recurring item. Our bear case target is $236.59, a 6.8% drawdown if patent cliffs bite harder than expected.

How JNJ Compares to Merck and Pfizer

Merck (NYSE:MRK) is the closest oncology-driven comp given KEYTRUDA’s dominance. Merck guides 2026 non-GAAP EPS of $8.93-$9.03 on revenue of $64.3B-$64.8B, but a $0.37 Cidara acquisition charge muddies the trailing picture. JNJ’s diversified MedTech plus Innovative Medicine mix looks cleaner, supporting our target’s forward P/E of roughly 23.

Pfizer (NYSE:PFE) trades at a trailing P/E of just 14 with a dividend yield near 6%, versus JNJ’s 30 P/E and 2.01% yield. Pfizer looks statistically cheaper, but the discount reflects post-COVID revenue erosion and patent-cliff risk. JNJ’s premium is earned, and our target leaves room versus the sell-side consensus of $259.

I’d Buy It Here

The 24/7 Wall St. price target of $277.85 with 90% confidence and a buy rating reflects a company hitting on innovation while paying investors to wait through a 64th consecutive dividend increase.

I’d be a buyer if the December 8 Enterprise Business Review confirms the double-digit growth path. I’d stay sidelined if litigation charges reaccelerate or if the Orthopaedics separation gets delayed.

Year 24/7 Wall St. Price Target
2026 $277.85
2027 $298.00
2028 $318.00
2029 $337.00
2030 $356.79

These projections assume JNJ executes on its path toward double-digit growth by decade’s end. Significant upside or downside could result from oncology pipeline outcomes or the Orthopaedics separation.

Contact [email protected] for any questions or corrections.

1INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE

Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org).2The probability of a member receiving $3,000 is 0.028%. If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Members must fund their account with a minimum of $50.00 to qualify. The probability percentage is subject to decrease. Members are only eligible for the Stock Award promotion upon opening their first brokerage account; subsequent cash brokerage accounts are ineligible for the promo, including for members with multiple accounts.

3Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees.

4There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event.
Vandita Jadeja

Vandita Jadeja is a financial publisher with over a decade of experience writing about financial topics, including investment, savings, retirement, insurance and banking. Vandita is a Chartered Accountant who loves to debunk financial concepts for readers.

Her work has appeared on sites that include The Motley Fool, InvestorPlace, and Benzinga. She covers investing and focuses on stock picks and price prediction for 24/7 Wall St.

When not looking for the next stock investment opportunity, she can be found traveling, reading, chasing sunsets and enjoying her iced latte.

All articles →